Literature DB >> 8515134

Virologic markers of human immunodeficiency virus type 1 in cerebrospinal fluid. The HIV Neurobehavioral Research Center Group.

S A Spector1, K Hsia, D Pratt, J Lathey, J A McCutchan, J E Alcaraz, J H Atkinson, S Gulevich, M Wallace, I Grant.   

Abstract

As part of a longitudinal study, 265 cerebrospinal fluid (CSF) specimens from 204 human immunodeficiency virus type 1 (HIV-1)-seropositive subjects and 43 seronegative controls were evaluated. Of the 204 seropositive persons, 78 (38%) had > or = 1 CSF culture positive for HIV-1; the probability of being culture positive increased as the number of CSF samples obtained increased (P = .0018). Significantly correlated with culture positivity were elevations in CSF protein level (P = .014) and CSF white blood cell count (P = .001). Virus was more readily cultured from clarified CSF (89%, 42/47) than from the cellular fraction (30%, 14/47; P < .00001). Amplification of HIV-1 DNA by polymerase chain reaction (PCR) from 25 seropositive persons was positive in 9 (82%) of 11 culture-positive and in 4 (29%) of 14 culture-negative specimens, while amplification of viral RNA detected all 11 culture-positive and 9 (64%) of the 14 culture-negative CSF specimens. These data support the hypothesis that the development of HIV-1-associated neurocognitive disorders are not dependent solely on the presence of HIV-1 within the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8515134     DOI: 10.1093/infdis/168.1.68

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Whole brain diffusion tensor imaging in HIV-associated cognitive impairment.

Authors:  Ann B Ragin; Pippa Storey; Bruce A Cohen; Leon G Epstein; Robert R Edelman
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

2.  Cerebrospinal fluid pleocytosis as a predictive factor for CSF and plasma HIV RNA discordance and escape.

Authors:  Sérgio Monteiro de Almeida; Indianara Rotta; Ana Paula de Pereira; Bin Tang; Anya Umlauf; Cléa Elisa Lopes Ribeiro; Scott Letendre; Ronald J Ellis
Journal:  J Neurovirol       Date:  2020-01-30       Impact factor: 2.643

Review 3.  Vertical human immunodeficiency virus-1 infection: involvement of the central nervous system and treatment.

Authors:  C Exhenry; D Nadal
Journal:  Eur J Pediatr       Date:  1996-10       Impact factor: 3.183

4.  Cholesterol-depleting statin drugs protect postmitotically differentiated human neurons against ethanol- and human immunodeficiency virus type 1-induced oxidative stress in vitro.

Authors:  Edward Acheampong; Zahida Parveen; Aschalew Mengistu; Noel Ngoubilly; Brian Wigdahl; Albert S Lossinsky; Roger J Pomerantz; Muhammad Mukhtar
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

5.  Cerebrospinal fluid HIV viral load in different phases of HIV-associated brain disease.

Authors:  Hans-Jürgen von Giesen; Ortwin Adams; Hubertus Köller; Gabriele Arendt
Journal:  J Neurol       Date:  2005-03-06       Impact factor: 4.849

Review 6.  NeuroAIDS: characteristics and diagnosis of the neurological complications of AIDS.

Authors:  Alireza Minagar; Deborah Commins; J Steven Alexander; Romy Hoque; Francesco Chiappelli; Elyse J Singer; Behrooz Nikbin; Paul Shapshak
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

7.  Intrathecal viral replication and cerebral deficits in different stages of human immunodeficiency virus disease.

Authors:  Gabriele Arendt; Thorsten Nolting; Christian Frisch; Ingo-Wilhelm Husstedt; Nora Gregor; Eleni Koutsilieri; Mattias Maschke; Alexander Angerer; Mark Obermann; Eva Neuen-Jacob; Ortwin Adams; Sabine Loeffert; Peter Riederer; Volker ter Meulen; Sieghart Sopper
Journal:  J Neurovirol       Date:  2007-06       Impact factor: 2.643

8.  The potential anesthetic threats, challenges and intensive care considerations in patients with HIV infection.

Authors:  Sukhminder Jit Singh Bajwa; Ashish Kulshrestha
Journal:  J Pharm Bioallied Sci       Date:  2013-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.